Stifel initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and $26 price target. The stock closed at $13.86 on Nov. 24.Read More
Roth Capital Partners reinitiated coverage of Savara (NASDAQ:SVRA) with a “buy” rating and $40 price target. The stock closed at $9.24 on Sept. 26.Read More
Leerink initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “market perform” rating and a $24 price target. The stock closed at $22.75 on July 21.Read More
Jaguar Animal Health (NASDAQ:JAGX) has signed an exclusive distribution agreement with JP Equine Services for distribution of Jaguar’s lead non-prescription products, Neonorm Foal and Neonorm Calf, in Japan.Read More
Roth Capital Partners initiated coverage of Poxel SA (NXT:PA) with a “buy” rating and price target of €11. The stock was recently quoted at €5.14.Read More
Ladenburg Thalmann initiated coverage of Albireo Pharma (NASDAQ:ALBO) with a “buy” rating and $40 price target. The stock closed at $20.28 on Feb. 15.Read More
Maxim Group downgraded Pluristem Therapeutics (NASDAQ:PSTI) to “hold” from “buy” and eliminated its price target, saying it is not in agreement with the company in terms of its clinical plans. The stock closed at $1.14 on Feb. 13.Read More
H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral” and raised its price target to $6 from $2 after a revision and update of its revenue and valuation models. The stock closed at $1.67 on Jan. 27.Read More
Closely-held Mati Therapeutics has been granted a U.S. patent covering a method of providing a sustained drug release to an eye using a proprietary punctal plug design placed in the punctum (tear duct) over a treatment period.
The patent, which expires in 2028, complements earlier issued U.S. patent claims directed to the proprietary punctal plug for non-invasive sustained delivery of topical drugs to the eye. The proprietary technology is used for multiple disease states with consistent, sustained efficacy.Read More
Maxim Group lowered its price target for Sucampo Pharmaceuticals (NASDAQ:SCMP) to $17 from $26, citing a combination of the market environment and an assessment of the catalysts and risks. The stock was quoted at $11.89 at afternoon trading on Monday.
Analyst Jason Kolbert writes that he expects Sucampo’s stock to be driven by the quarterly sales progress associated with Amitiza, integration progress with RJ Ueno (Japan), and future product acquisitions.Read More
Merck KGaA of Germany (XETRA:MRK.DE) has received approval from the Japanese Ministry of Health, Labour and Welfare for Juniper Pharmaceuticals’ (NASDAQ:JNP) OneCrinone 90 mg (progesterone) for the indication of luteal phase supplementation in assisted reproductive treatment.
“This approval further expands the global Crinone progesterone gel franchise into the world’s’ third largest pharmaceutical market, giving women and couples struggling with infertility in Japan a new, patient-friendly therapeutic option for luteal phase support,” Frank Condella, CEO of Juniper, said in a statement. “We look forward to supporting the launch of OneCrinone in Japan later this year.”Read More
Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.
“We are delighted to receive a Locilex patent in Japan, the third largest pharmaceuticals market in the world,” David Luci, president and CEO, said in a statement.Read More
Rodman & Renshaw has started coverage of BioSpecifics Technologies (NASDAQ:BSTC) with a “buy” rating and 12-month price target of $60. The stock closed at $35.97 on Monday.
The company’s sole product is the collagenase clostridium histolyticum (CCH) for injection, which is approved for the treatment of Dupuytren’s contracture and Peyronie’s disease both in the U.S. and Europe. CCH also recently received regulatory approval in Japan for Dupuytren’s contracture and in Switzerland for Peyronie’s disease.Read More